|
FI94339C
(fi)
|
1989-07-21 |
1995-08-25 |
Warner Lambert Co |
Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
|
|
ES2087997T3
(es)
|
1990-01-12 |
1996-08-01 |
Cell Genesys Inc |
Generacion de anticuerpos xenogenicos.
|
|
JP2648897B2
(ja)
|
1991-07-01 |
1997-09-03 |
塩野義製薬株式会社 |
ピリミジン誘導体
|
|
WO1993000807A1
(en)
|
1991-07-03 |
1993-01-21 |
Cryolife, Inc. |
Method for stabilization of biomaterials
|
|
DE69333928T2
(de)
|
1992-04-30 |
2006-08-17 |
Probitas Pharma Inc., Los Angeles |
Verbesserte solubilisierung und stabilisierung des faktor viii-komplexes
|
|
US6177401B1
(en)
|
1992-11-13 |
2001-01-23 |
Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften |
Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
|
|
GB9410534D0
(en)
|
1994-05-26 |
1994-07-13 |
Lynxvale Ltd |
Improvements in or relating to growth factor inhibitors
|
|
US6267958B1
(en)
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
|
US6685940B2
(en)
|
1995-07-27 |
2004-02-03 |
Genentech, Inc. |
Protein formulation
|
|
JPH09154588A
(ja)
|
1995-10-07 |
1997-06-17 |
Toagosei Co Ltd |
Ｖｅｇｆ結合性ポリペプチド
|
|
JP2000509018A
(ja)
|
1996-03-26 |
2000-07-18 |
イーライ・リリー・アンド・カンパニー |
肥満タンパク質製剤
|
|
US6100071A
(en)
|
1996-05-07 |
2000-08-08 |
Genentech, Inc. |
Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
|
|
EP0852951A1
(de)
|
1996-11-19 |
1998-07-15 |
Roche Diagnostics GmbH |
Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
|
|
US7312196B2
(en)
|
1997-01-08 |
2007-12-25 |
Amylin Pharmaceuticals, Inc. |
Formulations for amylin agonist peptides
|
|
US20070224663A1
(en)
|
1997-03-07 |
2007-09-27 |
Human Genome Sciences, Inc. |
Human Secreted Proteins
|
|
US6171586B1
(en)
|
1997-06-13 |
2001-01-09 |
Genentech, Inc. |
Antibody formulation
|
|
WO1999038495A2
(en)
|
1998-01-30 |
1999-08-05 |
Scios Inc. |
Controlled release delivery of peptide or protein
|
|
US7001892B1
(en)
|
1999-06-11 |
2006-02-21 |
Purdue Research Foundation |
Pharmaceutical materials and methods for their preparation and use
|
|
EP1514933A1
(en)
|
1999-07-08 |
2005-03-16 |
Research Association for Biotechnology |
Secretory protein or membrane protein
|
|
US7129338B1
(en)
|
1999-07-08 |
2006-10-31 |
Research Association For Biotechnology |
Secretory protein or membrane protein
|
|
US7029895B2
(en)
|
1999-09-27 |
2006-04-18 |
Millennium Pharmaceuticals, Inc. |
27411, a novel human PGP synthase
|
|
CA2399727A1
(en)
|
2000-02-07 |
2001-08-09 |
Millennium Pharmaceuticals, Inc. |
Narc-1, subtilase-like homologs
|
|
US6629949B1
(en)
|
2000-05-08 |
2003-10-07 |
Sterling Medivations, Inc. |
Micro infusion drug delivery device
|
|
US6659982B2
(en)
|
2000-05-08 |
2003-12-09 |
Sterling Medivations, Inc. |
Micro infusion drug delivery device
|
|
WO2002020767A2
(en)
|
2000-09-08 |
2002-03-14 |
Massachusetts Institute Of Technology |
G-csf analog compositions and methods
|
|
PT1324776E
(pt)
|
2000-10-12 |
2009-12-23 |
Genentech Inc |
Formulações de proteína concentradas de viscosidade reduzida
|
|
US6596541B2
(en)
|
2000-10-31 |
2003-07-22 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
|
US20030133939A1
(en)
|
2001-01-17 |
2003-07-17 |
Genecraft, Inc. |
Binding domain-immunoglobulin fusion proteins
|
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
|
WO2003009817A2
(en)
|
2001-07-25 |
2003-02-06 |
Protein Design Labs, Inc. |
Stable lyophilized pharmaceutical formulation of igg antibodies
|
|
US20040101920A1
(en)
|
2002-11-01 |
2004-05-27 |
Czeslaw Radziejewski |
Modification assisted profiling (MAP) methodology
|
|
AU2003293543A1
(en)
|
2002-12-13 |
2004-07-09 |
Abgenix, Inc. |
System and method for stabilizing antibodies with histidine
|
|
HRP20050934B1
(hr)
|
2003-04-04 |
2014-09-26 |
Genentech, Inc. |
Formulacije s visokom koncentracijom antitijela i proteina
|
|
EP1471152A1
(en)
|
2003-04-25 |
2004-10-27 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Mutations in the human PCSK9 gene associated to hypercholesterolemia
|
|
US7850962B2
(en)
|
2004-04-20 |
2010-12-14 |
Genmab A/S |
Human monoclonal antibodies against CD20
|
|
US20110313024A1
(en)
|
2004-08-20 |
2011-12-22 |
Leonid Beigelman |
RNA INTERFERENCE MEDIATED INHIBITION OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9 (PCSK9) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
|
US20060147945A1
(en)
|
2005-01-06 |
2006-07-06 |
Edmonds Brian T |
Novel secreted proteins and their uses
|
|
CA3044969A1
(en)
|
2006-05-05 |
2007-12-21 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating gene expression
|
|
ES2366973T3
(es)
|
2006-05-05 |
2011-10-27 |
Isis Pharmaceuticals, Inc. |
Compuestos y procedimiento para modular la expresión génica.
|
|
EP2194128B1
(en)
|
2006-05-11 |
2012-08-01 |
Alnylam Pharmaceuticals Inc. |
Compositions and methods for inhibiting expression of the PCSK9 gene
|
|
EP3753548A1
(en)
|
2006-06-16 |
2020-12-23 |
Regeneron Pharmaceuticals, Inc. |
Vegf antagonist formulations suitable for intravitreal administration
|
|
US7572618B2
(en)
|
2006-06-30 |
2009-08-11 |
Bristol-Myers Squibb Company |
Polynucleotides encoding novel PCSK9 variants
|
|
US7608693B2
(en)
|
2006-10-02 |
2009-10-27 |
Regeneron Pharmaceuticals, Inc. |
High affinity human antibodies to human IL-4 receptor
|
|
WO2008057457A2
(en)
|
2006-11-07 |
2008-05-15 |
Merck & Co., Inc. |
Antagonists of pcsk9
|
|
CA2667989A1
(en)
|
2006-11-07 |
2008-11-06 |
Merck & Co., Inc. |
Antagonists of pcsk9
|
|
EP2083861A4
(en)
|
2006-11-07 |
2010-11-24 |
Merck Sharp & Dohme |
ANTAGONISTS OF PCSK9
|
|
WO2008057458A2
(en)
|
2006-11-07 |
2008-05-15 |
Merck & Co., Inc. |
Antagonists of pcsk9
|
|
CN101589143A
(zh)
*
|
2006-11-27 |
2009-11-25 |
Isis药物公司 |
用于治疗高胆固醇血症的方法
|
|
US8093222B2
(en)
|
2006-11-27 |
2012-01-10 |
Isis Pharmaceuticals, Inc. |
Methods for treating hypercholesterolemia
|
|
WO2008125623A2
(en)
|
2007-04-13 |
2008-10-23 |
Novartis Ag |
Molecules and methods for modulating proprotein convertase subtilisin/kexin type 9 (pcsk9)
|
|
JOP20080381B1
(ar)
|
2007-08-23 |
2023-03-28 |
Amgen Inc |
بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
|
|
US20100286021A1
(en)
|
2007-09-25 |
2010-11-11 |
Qun-Yong Zhou |
Methods of Modulating Prokineticin 2 for Treatment of Stress Response and Anxiety-Related Disorders
|
|
SG2013014352A
(en)
|
2007-10-26 |
2014-09-26 |
Merck Sharp & Dohme |
Anti-pcsk9 and methods for treating lipid and cholesterol disorders
|
|
AR070316A1
(es)
|
2008-02-07 |
2010-03-31 |
Merck & Co Inc |
Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
|
|
AR070315A1
(es)
|
2008-02-07 |
2010-03-31 |
Merck & Co Inc |
Anticuerpos 1b20 antagonistas de pcsk9
|
|
TWI700293B
(zh)
|
2008-04-11 |
2020-08-01 |
日商中外製藥股份有限公司 |
重複結合複數個抗原的抗體
|
|
TWI516501B
(zh)
|
2008-09-12 |
2016-01-11 |
禮納特神經系統科學公司 |
Ｐｃｓｋ９拮抗劑類
|
|
TR201802935T4
(tr)
|
2008-09-19 |
2018-03-21 |
Pfizer |
Stabil sıvı antikor formülasyonu.
|
|
TWI440469B
(zh)
|
2008-09-26 |
2014-06-11 |
Chugai Pharmaceutical Co Ltd |
Improved antibody molecules
|
|
WO2010068526A1
(en)
|
2008-12-12 |
2010-06-17 |
Merck Sharp & Dohme Corp. |
Pcsk9 immunoassay
|
|
JO3672B1
(ar)
|
2008-12-15 |
2020-08-27 |
Regeneron Pharma |
أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
|
|
US20130064834A1
(en)
|
2008-12-15 |
2013-03-14 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating hypercholesterolemia using antibodies to pcsk9
|
|
US8357371B2
(en)
|
2008-12-15 |
2013-01-22 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating hypercholesterolemia using antibodies to PCSK9
|
|
AU2010221156A1
(en)
|
2009-03-06 |
2011-09-22 |
Genentech, Inc. |
Antibody formulation
|
|
KR20120050429A
(ko)
|
2009-06-15 |
2012-05-18 |
알닐람 파마슈티칼스 인코포레이티드 |
Ｐｃｓｋ9 유전자를 표적으로 하는 지질 제형된 ｄｓｒｎａ
|
|
CN102695499A
(zh)
|
2009-06-18 |
2012-09-26 |
惠氏有限责任公司 |
小模块免疫药物的冻干制剂
|
|
US20110009628A1
(en)
|
2009-07-08 |
2011-01-13 |
Haiyan Liu |
Compounds and Compositions for Modulating Lipid Levels and Methods of Preparing Same
|
|
EP2456870A1
(en)
|
2009-07-21 |
2012-05-30 |
Santaris Pharma A/S |
Antisense oligomers targeting pcsk9
|
|
WO2011028938A1
(en)
|
2009-09-02 |
2011-03-10 |
Alnylam Pharmaceuticals, Inc. |
Methods for lowering serum cholestrol in a subject using inhibition of pcsk9
|
|
WO2011037791A1
(en)
|
2009-09-25 |
2011-03-31 |
Merck Sharp & Dohme Corp. |
Antagonists of pcsk9
|
|
WO2011039578A1
(en)
|
2009-10-02 |
2011-04-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Combination of spla2 activity and lp(a) cardiovascular risk factors for the diagnosis/prognosis of a cardiovascular disease/event
|
|
WO2011053759A1
(en)
|
2009-10-30 |
2011-05-05 |
Merck Sharp & Dohme Corp. |
Ax1 and ax189 pcsk9 antagonists and variants
|
|
EP2493507A4
(en)
|
2009-10-30 |
2013-11-20 |
Merck Sharp & Dohme |
AX213 AND AX132 PCSK9 ANTAGONISTS AND VARIANTS THEREOF
|
|
PT3721904T
(pt)
|
2009-11-20 |
2021-11-15 |
Biocon Ltd |
Formulações de anticorpo t1h
|
|
AR079336A1
(es)
|
2009-12-11 |
2012-01-18 |
Irm Llc |
Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
|
|
JO3417B1
(ar)
|
2010-01-08 |
2019-10-20 |
Regeneron Pharma |
الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
|
|
EP2545079A2
(en)
|
2010-03-11 |
2013-01-16 |
Rinat Neuroscience Corporation |
ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING
|
|
GB201005005D0
(en)
|
2010-03-25 |
2010-05-12 |
Angeletti P Ist Richerche Bio |
New vaccine
|
|
AU2011202239C1
(en)
|
2010-05-19 |
2017-03-16 |
Sanofi |
Long-acting formulations of insulins
|
|
DE102010024698A1
(de)
|
2010-06-23 |
2011-12-29 |
Eads Deutschland Gmbh |
Verfahren, Vorrichtung und Anordnung zur Entfernung organischer Verschmutzung von Anströmbereichen eines Luftfahrzeugs
|
|
PL2624865T3
(pl)
|
2010-10-06 |
2018-11-30 |
Regeneron Pharmaceuticals, Inc. |
Stabilizowane preparaty zawierające przeciwciała przeciwko receptorowi interleukiny-4 (IL-4R)
|
|
WO2012054438A1
(en)
|
2010-10-22 |
2012-04-26 |
Schering Corporation |
Anti-pcsk9
|
|
CA2817015A1
(en)
|
2010-11-09 |
2012-05-18 |
Altimab Therapeutics, Inc. |
Protein complexes for antigen binding and methods of use
|
|
CA2820953A1
(en)
|
2010-12-22 |
2012-06-28 |
Genentech, Inc. |
Anti-pcsk9 antibodies and methods of use
|
|
BR112013018740A2
(pt)
|
2011-01-28 |
2019-01-08 |
Sanofi Sa |
anticorpos humanos para pcsk9 para uso em métodos de tratamento de grupos específicos de indivíduos
|
|
CN103562227B
(zh)
|
2011-02-11 |
2016-12-21 |
诺瓦提斯公司 |
Pcsk9拮抗剂
|
|
AR088782A1
(es)
|
2011-04-29 |
2014-07-10 |
Sanofi Sa |
Sistemas de ensayo y metodos para identificar y caracterizar farmacos hipolipemiantes
|
|
US20140004122A1
(en)
|
2011-05-10 |
2014-01-02 |
Amgen Inc. |
Methods for treating or preventing cholesterol related disorders
|
|
JOP20200043A1
(ar)
|
2011-05-10 |
2017-06-16 |
Amgen Inc |
طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
|
|
CA2840482C
(en)
|
2011-07-14 |
2018-10-16 |
Pfizer Inc. |
Treatment with anti-pcsk9 antibodies
|
|
AR087305A1
(es)
|
2011-07-28 |
2014-03-12 |
Regeneron Pharma |
Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
|
|
AR087715A1
(es)
|
2011-09-16 |
2014-04-09 |
Lilly Co Eli |
Anticuerpos anti pcsk9 y usos de los mismos
|
|
CN103930444B
(zh)
|
2011-09-16 |
2020-08-04 |
瑞泽恩制药公司 |
用前蛋白转化酶枯草溶菌素-9(PCSK9)抑制剂降低脂蛋白(a)水平的方法
|
|
US9663825B2
(en)
|
2012-04-19 |
2017-05-30 |
Acetylon Pharmaceuticals, Inc. |
Biomarkers to identify patients that will respond to treatment and treating such patients
|
|
EA039663B1
(ru)
|
2012-05-03 |
2022-02-24 |
Амген Инк. |
Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
|
|
TWI596115B
(zh)
|
2012-08-13 |
2017-08-21 |
再生元醫藥公司 |
具有ｐＨ－依賴性結合特性之抗－ＰＣＳＫ９抗體
|
|
EP2703008A1
(en)
|
2012-08-31 |
2014-03-05 |
Sanofi |
Human antibodies to PCSK9 for use in methods of treating particular groups of subjects
|
|
EP2703009A1
(en)
|
2012-08-31 |
2014-03-05 |
Sanofi |
Combination treatments involving antibodies to human PCSK9
|
|
EP2706070A1
(en)
|
2012-09-06 |
2014-03-12 |
Sanofi |
Combination treatments involving antibodies to human PCSK9
|
|
TWI682780B
(zh)
|
2013-05-30 |
2020-01-21 |
美商再生元醫藥公司 |
醫藥組成物用於製造治療與ｐｃｓｋ９功能獲得性突變有關之體染色體顯性高膽固醇血症的藥物之用途
|
|
US10111953B2
(en)
|
2013-05-30 |
2018-10-30 |
Regeneron Pharmaceuticals, Inc. |
Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
|
|
TW202021614A
(zh)
|
2013-06-07 |
2020-06-16 |
法商賽諾菲生物技術公司 |
藉由投與ｐｃｓｋ９抑制劑抑制動脈粥狀硬化的方法
|
|
EP3689913B1
(en)
|
2013-10-11 |
2022-03-23 |
Sanofi Biotechnology |
Use of a pcsk9 inhibitor to treat hyperlipidemia
|
|
US10428157B2
(en)
|
2013-11-12 |
2019-10-01 |
Sanofi Biotechnology |
Dosing regimens for use with PCSK9 inhibitors
|
|
US9034332B1
(en)
|
2014-07-15 |
2015-05-19 |
Kymab Limited |
Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
|
|
US8883157B1
(en)
|
2013-12-17 |
2014-11-11 |
Kymab Limited |
Targeting rare human PCSK9 variants for cholesterol treatment
|
|
US8945560B1
(en)
|
2014-07-15 |
2015-02-03 |
Kymab Limited |
Method of treating rheumatoid arthritis using antibody to IL6R
|
|
WO2015123423A2
(en)
|
2014-02-14 |
2015-08-20 |
Regeneron Pharmaceuticals, Inc |
Methods for treating patients with hypercholesterolemia that is not adequately controlled by moderate-dose statin therapy
|
|
US20150283236A1
(en)
|
2014-03-17 |
2015-10-08 |
Marie Baccara-Dinet |
Methods for treating subjects with primary hypercholesterolemia that is not adequately controlled
|
|
CN114642661A
(zh)
|
2014-03-17 |
2022-06-21 |
赛诺菲生物技术公司 |
用于降低心血管风险的方法
|
|
EP3169362B1
(en)
|
2014-07-16 |
2020-06-10 |
Sanofi Biotechnology |
Methods for treating high cardiovascular risk patients with hypercholesterolemia
|
|
KR20230074283A
(ko)
|
2014-07-16 |
2023-05-26 |
사노피 바이오테크놀로지 |
이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법
|
|
JP2018523684A
(ja)
|
2015-08-18 |
2018-08-23 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
リポタンパク質アフェレーシスを受けている高脂血症の患者を治療するための抗ｐｃｓｋ９阻害抗体
|
|
US20190031774A1
(en)
|
2017-06-09 |
2019-01-31 |
Sanofi Biotechnology |
Methods for treating hyperlipidemia in diabetic patients by administering a pcsk9 inhibitor
|